Filing Overview
The provided Form 10-Q identifies the registrant as AlloVir, Inc., not Kalaris Therapeutics, Inc. It covers the unaudited quarter and nine months ended September 30, 2020, and was filed November 10, 2020. AlloVir is a late clinical-stage biotechnology company developing allogeneic, off-the-shelf virus-specific T-cell therapies. Its lead candidate is Viralym-M, with additional candidates including ALVR106 and ALVR109.
Financial Position and Results
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0.0 million in 2020 and 2019 | $0.0 million in 2020 versus $0.2 million in 2019 |
| Research and development expense | $17.2 million versus $5.7 million | $32.9 million versus $9.6 million |
| General and administrative expense | $6.7 million versus $2.8 million | $13.0 million versus $7.8 million |
| Total operating expenses | $23.9 million versus $8.5 million | $45.9 million versus $17.4 million |
| Net loss | $23.6 million versus $7.3 million | $44.6 million versus $15.1 million |
| Basic and diluted loss per share | $0.58 loss versus $4.97 loss | $2.93 loss versus $13.67 loss |
| Net cash used in operating activities | $39.7 million versus $11.3 million for the comparable nine-month period |
Because the company had no product revenue, gross and operating margins are not meaningful. The company has incurred recurring losses since inception and reported an accumulated deficit of $99.9 million at September 30, 2020.
- Cash and cash equivalents were $142.3 million, compared with $61.1 million at December 31, 2019.
- Short-term investments were $236.2 million, compared with $65.0 million at year-end 2019. Substantially all were U.S. Treasury securities with maturities within one year.
- Cash, cash equivalents and short-term investments totaled $378.5 million at September 30, 2020.
- Total liabilities were $19.8 million, including $9.5 million of operating lease liabilities. The filing states that the company had no debt outstanding.
- Stockholders’ equity was $373.9 million, compared with a deficit of $51.5 million at December 31, 2019.
Material Changes Versus Prior Comparable Period
- Third-quarter research and development expense increased by $11.5 million, primarily from greater Viralym-M manufacturing and clinical-trial activity, higher ALVR106 development costs, and increased personnel and consultant costs.
- Nine-month research and development expense increased by $23.3 million, including increases of $10.0 million for Viralym-M, $5.2 million for ALVR106 and $7.8 million in personnel-related costs.
- General and administrative expense increased by $3.9 million in the quarter and $5.2 million for the nine-month period, driven by higher headcount, professional fees, insurance and public-company preparation costs.
- Interest income declined as the investment portfolio and interest-rate environment changed; total other income, net declined to $0.3 million in the quarter and $1.3 million for the nine months.
- The company completed its initial public offering on August 3, 2020, issuing 18,687,500 shares at $17.00 per share and receiving approximately $292.0 million of net proceeds. Existing convertible preferred stock converted into 39,859,139 common shares.
- Shares outstanding increased materially following the IPO and preferred-stock conversion. The company reported 61,659,533 common shares outstanding at September 30, 2020 and 65,106,873 shares outstanding as of November 9, 2020.
Liquidity, Cash Flow and Outlook
- Operating cash use increased to $39.7 million for the first nine months of 2020, reflecting higher research and development and corporate spending.
- Investing cash use was $171.4 million, primarily due to purchases of short-term investments totaling $242.4 million, partly offset by $71.0 million of maturities.
- Financing cash flow was $292.3 million, primarily from IPO proceeds.
- Management stated that available cash, cash equivalents and short-term investments were sufficient to fund planned operations for at least twelve months from issuance of the financial statements and expected to support operations and capital expenditures into 2023. This estimate depends on assumptions that may prove inaccurate.
- The company expects operating losses and expenses to increase as it advances clinical programs, expands manufacturing activities, hires personnel and incurs additional public-company costs. It expects to require substantial additional funding and has no committed source of additional capital.
Development, Risks and Unusual Items
- Viralym-M had completed a proof-of-concept trial and was entering initial pivotal trials for virus-associated hemorrhagic cystitis in the fourth quarter of 2020. The company planned three Phase 3 and three Phase 2 trials for Viralym-M in 2020 and 2021.
- The company anticipated filing an IND for ALVR106 in the second half of 2020 and planned a Phase 1/2 study in 2021. BCM had initiated a proof-of-concept trial for ALVR109, targeting SARS-CoV-2.
- The COVID-19 pandemic had interrupted or delayed clinical and preclinical activities and could disrupt patient enrollment, clinical sites, CROs, suppliers and contract manufacturing organizations.
- An ALVR109 IND submitted by BCM was placed on clinical hold in July 2020 due to safety concerns regarding ancillary reagents; the FDA subsequently lifted the hold and cleared the IND.
- Manufacturing remains dependent on third parties, limited suppliers and specialized cell-therapy processes. Qualification and commissioning of the ElevateBio BaseCamp facility were expected to continue through 2021.
- The company relies substantially on intellectual property licensed from BCM. The BCM arrangements include development obligations, potential milestone payments exceeding $40.0 million, tiered royalties generally ranging from less than 1% to low single digits on net sales, and termination provisions.
- The company is dependent on Viralym-M and has no approved products or product sales. Clinical failure, regulatory delays, manufacturing problems, adverse events, competition or inability to obtain financing could materially impair the business.
- The company reported no material legal proceedings and no material off-balance-sheet arrangements.
- Management stated that disclosure controls and procedures were effective as of September 30, 2020. A prior material weakness related to the 2018 corporate conversion was considered remediated or no longer applicable after the IPO and preferred-stock conversion.
Investor Verification Checklist
- Confirm that the filing and financial data relate to AlloVir, Inc., rather than Kalaris Therapeutics, Inc.
- Verify the IPO proceeds, share issuance, preferred-stock conversion and resulting dilution.
- Assess whether the stated cash runway into 2023 remains reasonable given the rising clinical, manufacturing and public-company spending profile.
- Track pivotal-trial initiation, enrollment, clinical outcomes and regulatory interactions for Viralym-M.
- Verify the status of ALVR106 and ALVR109 IND filings, clinical trials and any additional clinical holds.
- Evaluate COVID-19 effects on trial timelines, manufacturing capacity, supply availability and patient enrollment.
- Review BCM license obligations, milestone exposure, royalty terms and potential termination triggers.
- Monitor reliance on ElevateBio, external manufacturers, single-source suppliers and the completion of BaseCamp qualification activities.
- Consider future financing needs and potential dilution, including equity-plan and option-related share issuances.